It is estimated that more than one million heart failure hospitalizations occur each year.Systolic heart failure and heart failure with preserved ejection fract
In February 2004, bevacizumab (Avastin; Genentech), an antibody against vascularendothelial growth factor, was approved by the US FDA for the first-line treatme